Tuberculosis: The drug development pipeline at a glance

European Journal of Medicinal Chemistry

Volumn 51, Issue , 2012, Pages 1-16

  Villemagne, Baptiste ^a,b,c,d   Crauste, Céline ^a,b,c,d   Flipo, Marion ^a,b,c,d   Baulard, Alain R ^a,c,d,e   Déprez, Benoit ^a,b,c,d   Willand, Nicolas ^a,b,c,d  

^a UNIV LILLE   (France)

^b INSERM   (France)

^c IPL   (France)

^d PRIM   (France)

^e INSERM U1019   (France)

Author keywords

Drug discovery and drug development; Mycobacterium tuberculosis; New molecular entities

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMINOSALICYLIC ACID; AZD 5847; BDM 31343; BEDAQUILINE; BTZ 043; CYCLOSERINE; DC 159A; DELAMANID; DNB 1; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PYRAZINAMIDE; RIFAMPICIN; SQ 609; STREPTOMYCIN; SUTEZOLID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; REVIEW; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; TUBERCULOSIS;

EID: 84860295215     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.02.033     Document Type: Review

References (153)

1. World Health Organization Global Tuberculosis Control 2011 978 92 4 156438 0
2. H.S. Cox, N. Ford, and J.C. Reeder Are we really that good at treating tuberculosis? Lancet Infect. Dis. 9 2009 138 139
3. G. Elzinga, M.C. Raviglione, and D. Maher Scale up: meeting targets in global tuberculosis control Lancet 363 2004 814 819 (Pubitemid 38315173)
4. C. Dye, and B.G. Williams The population dynamics and control of tuberculosis Science 328 2010 856 861
5. Y. Zhang The magic bullets and tuberculosis drug targets Annu. Rev. Pharmacol. Toxicol. 45 2005 529 564 (Pubitemid 40261816)
6. A. Schatz, and S.A. Waksman Effect of streptomycin and other antibiotic substances upon Mycobacterium tuberculosis and related organisms Proc. Soc. Exp. Biol. Med. 57 1944 244 248
7. A.P. Carter, W.M. Clemons, D.E. Brodersen, R.J. Morgan-Warren, B.T. Wimberly, and V. Ramakrishnan Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics Nature 407 2000 340 348
8. R.T. Garvin, D.K. Biswas, and L. Gorini The effects of streptomycin or dihydrostreptomycin binding to 16S RNA or to 30S ribosomal subunits Proc. Natl. Acad. Sci. U S A 71 1974 3814 3818
9. J. Bernstein, W.A. Lott, B.A. Steinberg, and H.L. Yale Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds Am. Rev. Tuberc. 65 1952 357 364
10. J. Rengarajan, C.M. Sassetti, V. Naroditskaya, A. Sloutsky, B.R. Bloom, and E.J. Rubin The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria Mol. Microbiol. 53 2004 275 282 (Pubitemid 38901397)
11. G.S. Timmins, and V. Deretic Mechanisms of action of isoniazid Mol. Microbiol. 62 2006 1220 1227 (Pubitemid 44707189)
12. F.G. Winder, and P.B. Collins Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis J. Gen. Microbiol. 63 1970 41 48
13. L. Malone, A. Schurr, H. Lindh, D. McKenzie, J.S. Kiser, and J.H. Williams The effect of pyrazinamide (aldinamide) on experimental tuberculosis in mice Am. Rev. Tuberc. 65 1952 511 518
14. Y. Zhang, and D. Mitchison The curious characteristics of pyrazinamide: a review Int. J. Tubercul. Lung Dis. 7 2003 6 21 (Pubitemid 36427026)
15. Y. Zhang, M.M. Wade, A. Scorpio, H. Zhang, and Z. Sun Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid J. Antimicrob. Chemother. 52 2003 790 795 (Pubitemid 37407806)
16. W. Shi, X. Zhang, X. Jiang, H. Yuan, J.S. Lee, C.E. Barry, H. Wang, W. Zhang, and Y. Zhang Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis Science 333 2011 1630 1632
17. J.P. Thomas, C.O. Baughn, R.G. Wilkinson, and R.G. Shepherd A new synthetic compound with antituberculous activity in mice: ethambutol (dextro-2,2'-(ethylenediimino)-di-l-butanol) Am. Rev. Respir. Dis. 83 1961 891 893
18. A.E. Belanger, G.S. Besra, M.E. Ford, K. Mikusova, J.T. Belisle, P.J. Brennan, and J.M. Inamine The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol Proc. Natl. Acad. Sci. U S A 93 1996 11919 11924 (Pubitemid 26347224)
19. G. Binda, E. Domenichini, A. Gottardi, B. Orlandi, E. Ortelli, B. Pacini, and G. Fowst Rifampicin, a general review Arzneimittelforschung 21 1971 1907 1977
20. N. Maggi, C.R. Pasqualucci, R. Ballotta, and P. Sensi Rifampicin: a new orally active rifamycin Chemotherapy 11 1966 285 292
21. W.R. McClure, and C.L. Cech On the mechanism of rifampicin inhibition of RNA synthesis J. Biol. Chem. 253 1978 8949 8956 (Pubitemid 9117005)
22. D. Libermann, M. Moyeux, N. Rist, and F. Grumbach Preparation of new pyridinic thioamides active in experimental tuberculosis C. R. Hebd. Seances Acad. Sci. 242 1956 2409 2412
23. A. Banerjee, E. Dubnau, A. Quemard, V. Balasubramanian, K.S. Um, T. Wilson, D. Collins, G. de Lisle, and W.R. Jacobs Jr. INHA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis Science 263 1994 227 230 (Pubitemid 24067929)
24. Y. Zhang, B. Heym, B. Allen, D. Young, and S. Cole The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis Nature 358 1992 591 593
25. A.E. DeBarber, K. Mdluli, M. Bosman, L.G. Bekker, and C.E. Barry 3rd Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis Proc. Natl. Acad. Sci. U S A 97 2000 9677 9682 (Pubitemid 30650835)
26. A.R. Baulard, J.C. Betts, J. Engohang-Ndong, S. Quan, R.A. McAdam, P.J. Brennan, C. Locht, and G.S. Besra Activation of the pro-drug ethionamide is regulated in mycobacteria J. Biol. Chem. 275 2000 28326 28331
27. H.L. David, K. Takayama, and D.S. Goldman Susceptibility of mycobacterial d-alanyl-d-alanine synthetase to d-cycloserine Am. Rev. Respir. Dis. 100 1969 579 581
28. N.E. Caceres, N.B. Harris, J.F. Wellehan, Z. Feng, V. Kapur, and R.G. Barletta Overexpression of the d-alanine racemase gene confers resistance to d-cycloserine in Mycobacterium smegmatis J. Bacteriol. 179 1997 5046 5055 (Pubitemid 27340537)
29. Z. Feng, and R.G. Barletta Roles of Mycobacterium smegmatis d-Alanine:d-Alanine ligase and d-Alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor d-Cycloserine Antimicrob. Agents Chemother. 47 2003 283 291 (Pubitemid 36070376)
30. † Chem. Rev. 105 2005 775 792
31. W.H. Deitz, J.H. Bailey, and E.J. Froelich In vitro antibacterial properties of nalidixic acid, a new drug active against gram-negative organisms Antimicrob. Agents Chemother. 161 1963 583 587
32. A.M. Emmerson, and A.M. Jones The quinolones: decades of development and use J. Antimicrob. Chemother. 51 2003 13 20 (Pubitemid 36622100)
33. C. Levine, H. Hiasa, and K.J. Marians DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities Biochim. Biophys. Acta 1400 1998 29 43 (Pubitemid 28475094)
34. L.A. Mitscher Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents Chem. Rev. 105 2005 559 592 (Pubitemid 40351634)
35. A. Aubry, X.-S. Pan, L.M. Fisher, V. Jarlier, and E. Cambau Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity Antimicrob. Agents Chemother. 48 2004 1281 1288 (Pubitemid 38405482)
36. B. Gaudillire, and P. Berna Ann. Rep. Med. Chem. 35 2000 340 343
37. J.P. Sanchez, R.D. Gogliotti, J.M. Domagala, S.J. Gracheck, M.D. Huband, J.A. Sesnie, M.A. Cohen, and M.A. Shapiro The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents J. Med. Chem. 38 1995 4478 4487
38. U. Petersen, W. Schröck, D. Habich, A. Krebs, T. Schenke, T. Philipps, K. Grohe, R. Endermann, K.-D. Bremm, K.-G. Metzger, Quinolonecarboxylic acids, US 5480879 A (1996).
39. J.C. Rodríguez, M. Ruiz, A. Climent, and G. Royo In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis Int. J. Antimicrob. Agents 17 2001 229 231 (Pubitemid 32229902)
40. A. Aubry, N. Veziris, E. Cambau, C. Truffot-Pernot, V. Jarlier, and L.M. Fisher Novel gyrase mutations in quinolone-resistant and - hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes Antimicrob. Agents Chemother. 50 2006 104 112 (Pubitemid 43042909)
41. Y. Hu, A.R.M. Coates, and D.A. Mitchison Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis Antimicrob. Agents Chemother. 47 2003 653 657 (Pubitemid 36158096)
42. E.J. Alvirez-Freites, J.L. Carter, and M.H. Cynamon In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis Antimicrob. Agents Chemother. 46 2002 1022 1025 (Pubitemid 34260345)
43. E.L. Nuermberger, T. Yoshimatsu, S. Tyagi, K. Williams, I. Rosenthal, R.J. O'Brien, A.A. Vernon, R.E. Chaisson, W.R. Bishai, and J.H. Grosset Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis Am. J. Respir. Crit. Care Med. 170 2004 1131 1134 (Pubitemid 39488628)
44. M. Ibrahim, C. Truffot-Pernot, K. Andries, V. Jarlier, and N. Veziris Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis Am. J. Respir. Crit. Care Med. 180 2009 553 557
45. E.L. Nuermberger, T. Yoshimatsu, S. Tyagi, R.J. O'Brien, A.N. Vernon, R.E. Chaisson, W.R. Bishai, and J.H. Grosset Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis Am. J. Respir. Crit. Care Med. 169 2004 421 426 (Pubitemid 38134824)
46. Moxifloxacin, Tuberculosis, 88 (2008) 127-131.
47. Gatifloxacin, Tuberculosis, 88 (2008) 109-111.
48. A. Lubasch, I. Keller, K. Borner, P. Koeppe, and H. Lode Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers Antimicrob. Agents Chemother. 44 2000 2600 2603
49. J.L. Johnson, D.J. Hadad, W.H. Boom, C.L. Daley, C.A. Peloquin, K.D. Eisenach, D.D. Jankus, S.M. Debanne, E.D. Charlebois, E. Maciel, M. Palaci, and R. Dietze Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis Int. J. Tubercul. Lung Dis. 10 2006 605 612 (Pubitemid 43845020)
50. M.W.R. Pletz, A. De Roux, A. Roth, K.-H. Neumann, H. Mauch, and H. Lode Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study Antimicrob. Agents Chemother. 48 2004 780 782 (Pubitemid 38280324)
51. J.-Y. Wang, J.-T. Wang, T.-H. Tsai, C.-L. Hsu, C.-J. Yu, P.-R. Hsueh, L.-N. Lee, and P.-C. Yang Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis Int. J. Tubercul. Lung Dis. 14 2010 65 71
52. S.E. Dorman, J.L. Johnson, S. Goldberg, G. Muzanye, N. Padayatchi, L. Bozeman, C.M. Heilig, J. Bernardo, S. Choudhri, J.H. Grosset, E. Guy, P. Guyadeen, M.C. Leus, G. Maltas, D. Menzies, E.L. Nuermberger, M. Villarino, A. Vernon, and R.E. Chaisson The tuberculosis trials, substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis Am. J. Respir. Crit. Care Med. 180 2009 273 280
53. M.B. Conde, A. Efron, C. Loredo, G.R.M. De Souza, N.P. Graa, M.C. Cezar, M. Ram, M.A. Chaudhary, W.R. Bishai, A.L. Kritski, and R.E. Chaisson Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial Lancet 373 2009 1183 1189
54. R. Rustomjee, C. Lienhardt, T. Kanyok, G.R. Davies, J. Levin, T. Mthiyane, C. Reddy, A.W. Sturm, F.A. Sirgel, J. Allen, D.J. Coleman, B. Fourie, and D.A. Mitchison A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis Int. J. Tubercul. Lung Dis. 12 2008 128 138 (Pubitemid 351212403)
55. L.R. Codecasa, G. Ferrara, M. Ferrarese, M.A. Morandi, V. Penati, C. Lacchini, P. Vaccarino, and G.B. Migliori Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs Respir. Med. 100 2006 1566 1572 (Pubitemid 44109116)
56. Gatifloxacin clinicaltrials.gov (NCT ID: NCT00216385).
57. Moxifloxacin clinicaltrials.gov (NCT ID: NCT00864383).
58. J. Guillemont, Quinoline derivatives and their use as mycobacterial inhibitors, WO/2004/011436 (2004).
59. N. Lounis, J. Guillemont, N. Veziris, A. Koul, V. Jarlier, and K. Andries R207910 (TMC207): a new antibiotic for the treatment of tuberculosis Med. Mal. Infect. 40 2010 383 390
60. A.C. Haagsma, I. Podasca, A. Koul, K. Andries, J. Guillemont, H. Lill, and D. Bald Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase PLoS ONE 6 2011 e23575
61. K. Andries, P. Verhasselt, J. Guillemont, H.W.H. Göhlmann, J.-M. Neefs, H. Winkler, J. Van Gestel, P. Timmerman, M. Zhu, E. Lee, P. Williams, D. de Chaffoy, E. Huitric, S. Hoffner, E. Cambau, C. Truffot-Pernot, N. Lounis, and V. Jarlier A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 307 2005 223 227 (Pubitemid 40116230)
62. A. Koul, N. Dendouga, K. Vergauwen, B. Molenberghs, L. Vranckx, R. Willebrords, Z. Ristic, H. Lill, I. Dorange, J. Guillemont, D. Bald, and K. Andries Diarylquinolines target subunit c of mycobacterial ATP synthase Nat. Chem. Biol. 3 2007 323 324 (Pubitemid 46789271)
63. A.C. Haagsma, R. Abdillahi-Ibrahim, M.J. Wagner, K. Krab, K. Vergauwen, J. Guillemont, K. Andries, H. Lill, A. Koul, and D. Bald Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue Antimicrob. Agents Chemother. 53 2009 1290 1292
64. A. Koul, L. Vranckx, N. Dendouga, W. Balemans, I. Van den Wyngaert, K. Vergauwen, H.W.H. Göhlmann, R. Willebrords, A. Poncelet, J. Guillemont, D. Bald, and K. Andries Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis J. Biol. Chem. 283 2008 25273 25280
65. N. Lounis, N. Veziris, A. Chauffour, C. Truffot-Pernot, K. Andries, and V. Jarlier Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration Antimicrob. Agents Chemother. 50 2006 3543 3547 (Pubitemid 44684863)
66. N. Veziris, C. Truffot-Pernot, A. Aubry, V. Jarlier, and N. Lounis Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo Antimicrob. Agents Chemother. 47 2003 3117 3122 (Pubitemid 37229566)
67. N. Veziris, M. Ibrahim, N. Lounis, K. Andries, and V. Jarlier Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis PLoS ONE 6 2011 e17556
68. N. Lounis, T. Gevers, J. Van Den Berg, and K. Andries Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model Antimicrob. Agents Chemother. 52 2008 3568 3572
69. R. Rustomjee, A.H. Diacon, J. Allen, A. Venter, C. Reddy, R.F. Patientia, T.C. Mthiyane, T. De Marez, R. van Heeswijk, R. Kerstens, A. Koul, K. De Beule, P.R. Donald, and D.F. McNeeley Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis Antimicrob. Agents Chemother. 52 2008 2831 2835
70. A.H. Diacon, A. Pym, M. Grobusch, R. Patientia, R. Rustomjee, L. Page-Shipp, C. Pistorius, R. Krause, M. Bogoshi, G. Churchyard, A. Venter, J. Allen, J.C. Palomino, T. De Marez, R.P.G. van Heeswijk, N. Lounis, P. Meyvisch, J. Verbeeck, W. Parys, K. de Beule, K. Andries, and D.F.M. Neeley The diarylquinoline TMC207 for multidrug-resistant tuberculosis N. Engl. J. Med. 360 2009 2397 2405
71. T. De Marez TMC207 2011 WGND Annual Meeting Lille, France
72. TMC207 clinicaltrials.gov (NCT ID: NCT01464762).
73. L.G. Wayne, and H.A. Sramek Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis Antimicrob. Agents Chemother. 38 1994 2054 2058 (Pubitemid 24278800)
74. D.I. Edwards Mechanism of antimicrobial action of metronidazole J. Antimicrob. Chemother. 5 1979 499 502 (Pubitemid 10235169)
75. J.V. Brooks, S.K. Furney, and I.M. Orme Metronidazole therapy in mice infected with tuberculosis Antimicrob. Agents Chemother. 43 1999 1285 1288 (Pubitemid 29214765)
76. Metronidazole clinicaltrials.gov (NCT ID: NCT00425113).
77. K.C. Agrawal, K.B. Bears, R.K. Sehgal, J.N. Brown, P.E. Rist, and W.D. Rupp Potential radiosensitizing agents. Dinitroimidazoles J. Med. Chem. 22 1979 583 586 (Pubitemid 10230625)
78. K. Nagarajan, R.G. Shankar, S. Rajappa, S.J. Shenoy, and R. Costa-Pereira Nitroimidazoles XXI 2,3-dihydro-6-nitroimidazo [2,1-b] oxazoles with antitubercular activity Eur. J. Med. Chem. 24 1989 631 633 (Pubitemid 20025798)
79. D.R. Ashtekar, R. Costa-Perira, K. Nagrajan, N. Vishvanathan, A.D. Bhatt, and W. Rittel In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis Antimicrob. Agents Chemother. 37 1993 183 186 (Pubitemid 23046551)
80. W.R. Baker, C. Shaopei, E.L. Keeler, Nitroimidazole antibacterial compounds and methods of use thereof, WO/1997/001562 (1997).
81. C.K. Stover, P. Warrener, D.R. VanDevanter, D.R. Sherman, T.M. Arain, M.H. Langhorne, S.W. Anderson, J.A. Towell, Y. Yuan, D.N. McMurray, B.N. Kreiswirth, C.E. Barry, and W.R. Baker A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis Nature 405 2000 962 966 (Pubitemid 30435054)
82. U.H. Manjunatha, H. Boshoff, C.S. Dowd, L. Zhang, T.J. Albert, J.E. Norton, L. Daniels, T. Dick, S.S. Pang, and C.E. Barry Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis Proc. Natl. Acad. Sci. U S A 103 2006 431 436 (Pubitemid 43122418)
83. U.H. Manjunatha, R. Lahiri, B. Randhawa, C.S. Dowd, J.L. Krahenbuhl, and C.E. Barry Mycobacterium leprae is naturally resistant to PA-824 Antimicrob. Agents Chemother. 50 2006 3350 3354 (Pubitemid 44527509)
84. R. Singh, U. Manjunatha, H.I.M. Boshoff, Y.H. Ha, P. Niyomrattanakit, R. Ledwidge, C.S. Dowd, I.Y. Lee, P. Kim, L. Zhang, S. Kang, T.H. Keller, J. Jiricek, and C.E. Barry PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release Science 322 2008 1392 1395 (Pubitemid 352775253)
85. U. Manjunatha, H.I. Boshoff, and C.E. Barry The mechanism of action of PA-824: novel insights from transcriptional profiling Commun. Integr. Biol. 2 2009 215 218
86. A.J. Lenaerts, V. Gruppo, K.S. Marietta, C.M. Johnson, D.K. Driscoll, N.M. Tompkins, J.D. Rose, R.C. Reynolds, and I.M. Orme Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models Antimicrob. Agents Chemother. 49 2005 2294 2301 (Pubitemid 40734457)
87. S. Tyagi, E. Nuermberger, T. Yoshimatsu, K. Williams, I. Rosenthal, N. Lounis, W. Bishai, and J. Grosset Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis Antimicrob. Agents Chemother. 49 2005 2289 2293 (Pubitemid 40734456)
88. Z. Ahmad, C.A. Peloquin, R.P. Singh, H. Derendorf, S. Tyagi, A. Ginsberg, J.H. Grosset, and E.L. Nuermberger PA-824 exhibits time-dependent activity in a murine model of tuberculosis Antimicrob. Agents Chemother. 55 2011 239 245
89. Y. Hu, A.R.M. Coates, and D.A. Mitchison Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis Int. J. Tubercul. Lung Dis. 12 2008 69 73
90. E. Nuermberger, S. Tyagi, R. Tasneen, K.N. Williams, D. Almeida, I. Rosenthal, and J.H. Grosset Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis Antimicrob. Agents Chemother. 52 2008 1522 1524 (Pubitemid 351522025)
91. R. Tasneen, S. Tyagi, K. Williams, J. Grosset, and E. Nuermberger Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis Antimicrob. Agents Chemother. 52 2008 3664 3668
92. J.C. Sung, L. Garcia-Contreras, J.L. VerBerkmoes, C.A. Peloquin, K.J. Elbert, A.J. Hickey, and D.A. Edwards Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation Antimicrob. Agents Chemother. 53 2009 1338 1343
93. L. Garcia-Contreras, J.C. Sung, P. Muttil, D. Padilla, M. Telko, J.L. VerBerkmoes, K.J. Elbert, A.J. Hickey, and D.A. Edwards Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs Antimicrob. Agents Chemother. 54 2010 1436 1442
94. A.M. Ginsberg, M.W. Laurenzi, D.J. Rouse, K.D. Whitney, and M.K. Spigelman Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects Antimicrob. Agents Chemother. 53 2009 3720 3725
95. A.M. Ginsberg, M.W. Laurenzi, D.J. Rouse, K.D. Whitney, and M.K. Spigelman Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects Antimicrob. Agents Chemother. 53 2009 3726 3733
96. A.H. Diacon, R. Dawson, M. Hanekom, K. Narunsky, S.J. Maritz, A. Venter, P.R. Donald, C. van Niekerk, K. Whitney, D.J. Rouse, M.W. Laurenzi, A.M. Ginsberg, and M.K. Spigelman Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients Antimicrob. Agents Chemother. 54 2010 3402 3407
97. PA-824 clinicaltrials.gov (NCT ID: NCT01215851 and NCT00944021).
98. H. Sasaki, Y. Haraguchi, M. Itotani, H. Kuroda, H. Hashizume, T. Tomishige, M. Kawasaki, M. Matsumoto, M. Komatsu, and H. Tsubouchi Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles J. Med. Chem. 49 2006 7854 7860 (Pubitemid 46033674)
99. M. Matsumoto, H. Hashizume, T. Tomishige, M. Kawasaki, H. Tsubouchi, H. Sasaki, Y. Shimokawa, and M. Komatsu OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice PLoS Med. 3 2006 e466
100. A.H. Diacon, R. Dawson, M. Hanekom, K. Narunsky, A. Venter, N. Hittel, L.J. Geiter, C.D. Wells, A.J. Paccaly, and P.R. Donald Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients Int. J. Tubercul. Lung Dis. 15 2011 949 954
101. OPC-67683 clinicaltrials.gov (NCT ID: NCT01131351 and NCT00685360).
102. M. Protopopova, C. Hanrahan, B. Nikonenko, R. Samala, P. Chen, J. Gearhart, L. Einck, and C.A. Nacy Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines J. Antimicrob. Chemother. 56 2005 968 974 (Pubitemid 41631930)
103. R.E. Lee, M. Protopopova, E. Crooks, R.A. Slayden, M. Terrot, and C.E. Barry Combinatorial lead optimization of [1,2]-Diamines based on ethambutol as potential antituberculosis preclinical candidates J. Comb. Chem. 5 2003 172 187 (Pubitemid 37123511)
104. O.K. Onajole, P. Govender, P.D.v. Helden, H.G. Kruger, G.E.M. Maguire, I. Wiid, and T. Govender Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates Eur. J. Med. Chem. 45 2010 2075 2079
105. L. Jia, L. Coward, G.S. Gorman, P.E. Noker, and J.E. Tomaszewski Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N′-(2- adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv J. Pharmacol. Exp. Ther. 315 2005 905 911 (Pubitemid 41500757)
106. P. Chen, J. Gearhart, M. Protopopova, L. Einck, and C.A. Nacy Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro J. Antimicrob. Chemother. 58 2006 332 337 (Pubitemid 44294944)
107. V.M. Reddy, L. Einck, K. Andries, and C.A. Nacy In vitro interactions between new antitubercular drug candidates SQ109 and TMC207 Antimicrob. Agents Chemother. 54 2010 2840 2846
108. B.V. Nikonenko, M. Protopopova, R. Samala, L. Einck, and C.A. Nacy Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs Antimicrob. Agents Chemother. 51 2007 1563 1565 (Pubitemid 46586854)
109. L. Jia, J.E. Tomaszewski, C. Hanrahan, L. Coward, P. Noker, G. Gorman, B. Nikonenko, and M. Protopopova Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug Br. J. Pharmacol. 144 2005 80 87 (Pubitemid 40192564)
110. L. Jia, P.E. Noker, L. Coward, G.S. Gorman, M. Protopopova, and J.E. Tomaszewski Interspecies pharmacokinetics and in vitro metabolism of SQ109 Br. J. Pharmacol. 147 2006 476 485 (Pubitemid 43355045)
111. SQ109 clinicaltrials.gov (NCT ID: NCT01218217).
112. S.J. Brickner, D.K. Hutchinson, M.R. Barbachyn, P.R. Manninen, D.A. Ulanowicz, S.A. Garmon, K.C. Grega, S.K. Hendges, D.S. Toops, C.W. Ford, and G.E. Zurenko Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections J. Med. Chem. 39 1996 673 679
113. M.R. Barbachyn, and C.W. Ford Oxazolidinone structure-activity relationships leading to linezolid Ang. Chem. Int. Ed. 42 2003 2010 2023 (Pubitemid 36604340)
114. B. Pearlman, A. W. Perrault, R. M. Barbachyn, R. P. Manninen, R. D. Toops, S. D. Houser, J. T. Fleck, Process to prepare oxazolidinones, WO/1997/037980 (1997).
115. Y. Zhang, K. Post-Martens, and S. Denkin New drug candidates and therapeutic targets for tuberculosis therapy Drug Discov. Today 11 2006 21 27 (Pubitemid 43227848)
116. J.W.C. Alffenaar, T. van der Laan, S. Simons, T.S. van der Werf, P.J. van de Kasteele, H. de Neeling, and D. van Soolingen Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480 Antimicrob. Agents Chemother. 55 2011 1287 1289
117. L. Alcala, M.J. Ruiz-Serrano, C. Perez-Fernandez Turegano, D. Garcia de Viedma, M. Diaz-Infantes, M. Marin-Arriaza, and E. Bouza In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs Antimicrob. Agents Chemother. 47 2003 416 417 (Pubitemid 36070399)
118. J.C. Rodríguez, M. Ruiz, M. López, and G. Royo In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis Int. J. Antimicrob. Agents 20 2002 464 467 (Pubitemid 35379989)
119. M.H. Cynamon, S.P. Klemens, C.A. Sharpe, and S. Chase Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model Antimicrob. Agents Chemother. 43 1999 1189 1191 (Pubitemid 29214745)
120. R. Dietze, D.J. Hadad, B. McGee, L.P.D. Molino, E.L.N. Maciel, C.A. Peloquin, D.F. Johnson, S.M. Debanne, K. Eisenach, W.H. Boom, M. Palaci, and J.L. Johnson Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis Am. J. Respir. Crit. Care Med. 178 2008 1180 1185
121. J. Fortun, P. Martin-Davila, E. Navas, M.J. Perez-Elias, J. Cobo, M. Tato, E.G.-G. De la Pedrosa, E. Gomez-Mampaso, and S. Moreno Linezolid for the treatment of multidrug-resistant tuberculosis J. Antimicrob. Chemother. 56 2005 180 185
122. I.N. Park, S.-B. Hong, Y.-M. Oh, M.-N. Kim, C.-M. Lim, S.D. Lee, Y. Koh, W.S. Kim, D.S. Kim, W.D. Kim, and T.S. Shim Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis J. Antimicrob. Chemother. 58 2006 701 704 (Pubitemid 44288145)
123. G.F. Schecter, C. Scott, L. True, A. Raftery, J. Flood, and S. Mase Linezolid in the treatment of multidrug-resistant tuberculosis Clin. Infect. Dis. 50 2010 49 55
124. M.R. Barbachyn, D.K. Hutchinson, S.J. Brickner, M.H. Cynamon, J.O. Kilburn, S.P. Klemens, S.E. Glickman, K.C. Grega, S.K. Hendges, D.S. Toops, C.W. Ford, and G.E. Zurenko Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity J. Med. Chem. 39 1996 680 685 (Pubitemid 26069690)
125. K.N. Williams, C.K. Stover, T. Zhu, R. Tasneen, S. Tyagi, J.H. Grosset, and E. Nuermberger Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model Antimicrob. Agents Chemother. 53 2009 1314 1319
126. K.N. Williams, S.J. Brickner, C.K. Stover, T. Zhu, A. Ogden, R. Tasneen, S. Tyagi, J.H. Grosset, and E.L. Nuermberger Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis Am. J. Respir. Crit. Care Med. 180 2009 371 376
127. PNU-100480 clinicaltrials.gov (NCT ID: NCT00871949 and NCT00990990).
128. R.S. Wallis, W.M. Jakubiec, V. Kumar, A.M. Silvia, D. Paige, D. Dimitrova, X. Li, L. Ladutko, S. Campbell, G. Friedland, M. Mitton-Fry, and P.F. Miller Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers J. Infect. Dis. 202 2009 745 751
129. R.S. Wallis, W. Jakubiec, V. Kumar, G. Bedarida, A. Silvia, D. Paige, T. Zhu, M. Mitton-Fry, L. Ladutko, S. Campbell, and P.F. Miller Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis Antimicrob. Agents Chemother. 55 2011 567 574
130. PNU-100480 clinicaltrials.gov (NCT ID: NCT01225640).
131. AZD5847 clinicaltrials.gov (NCT ID: NCT01037725 and NCT01116258).
132. V. Balasubramanian, S. Butler, AZD5847, WGND Annual Meeting, Lille, France (2011).
133. R. Okumura, T. Hirata, Y. Onodera, K. Hoshino, T. Otani, and T. Yamamoto Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae J. Antimicrob. Chemother. 62 2008 98 104 (Pubitemid 351865879)
134. Y. Onodera, T. Hirata, K. Hoshino, and T. Otani Dc-159a, A Novel Quinolone, Showed High Inhibitory Activity Against Altered Topoisomerases of Streptococcus Pneumonia and Mycobacterium Tuberculosis 2007 Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother, American Society for Microbiology Washington DC abstr. F1-2126
135. J.-i. Sekiguchi, A. Disratthakit, S. Maeda, and N. Doi Characteristic resistance mechanism of Mycobacterium tuberculosis to DC-159a, a new respiratory quinolone Antimicrob. Agents Chemother. 55 2011 3958 3960
136. A. Disratthakit, and N. Doi In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium Species Antimicrob. Agents Chemother. 54 2010 2684 2686
137. N. Doi, A. Disratthakit, S. Ogiso, U. S., Y. Kurosaka, In vivo efficacy of DC-159a, a new generation of respiratory quinolone, against experimental murine tuberculosis due to multi-drug-resistant Mycobacterium tuberculosis, Abstr. 46th Intersci. Conf. AntimIcrob. Agents Chemother, American Society for Microbiology, San Francisco., abstra. F1-0492 (2006).
138. Z. Ahmad, A. Minkowski, C.A. Peloquin, K.N. Williams, K.E. Mdluli, J.H. Grosset, and E.L. Nuermberger Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis Antimicrob. Agents Chemother. 55 2011 1781 1783
139. E. Bogatcheva, C. Hanrahan, P. Chen, J. Gearhart, K. Sacksteder, L. Einck, C. Nacy, and M. Protopopova Discovery of dipiperidines as new antitubercular agents Bioorg. Med. Chem. Lett. 20 2010 201 205
140. E. Bogatcheva, C. Hanrahan, B. Nikonenko, G. de los Santos, V. Reddy, P. Chen, F. Barbosa, L. Einck, C. Nacy, and M. Protopopova Identification of SQ609 as a lead compound from a library of dipiperidines Bioorg. Med. Chem. Lett. 21 2011 5353 5357
141. V. Makarov, G. Manina, K. Mikusova, U. Möllmann, O. Ryabova, B. Saint-Joanis, N. Dhar, M.R. Pasca, S. Buroni, A.P. Lucarelli, A. Milano, E. De Rossi, M. Belanova, A. Bobovska, P. Dianiskova, J. Kordulakova, C. Sala, E. Fullam, P. Schneider, J.D. McKinney, P. Brodin, T. Christophe, S. Waddell, P. Butcher, J. Albrethsen, I. Rosenkrands, R. Brosch, V. Nandi, S. Bharath, S. Gaonkar, R.K. Shandil, V. Balasubramanian, T. Balganesh, S. Tyagi, J. Grosset, G. Riccardi, and S.T. Cole Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis Science 324 2009 801 804
142. Z. Ge, R. Li, and T. Cheng An efficient synthesis of formylmethyl piperidine-1-carbodithioate diethyl acetal and analogs Synth. Commun. 29 1999 3191 3196 (Pubitemid 29357487)
143. V. Makarov, U. Möllmann, S.T. Cole, New benzothiazinone derivatives and their use as antibacterial agents, WO2007134625 (2007).
144. M.R. Pasca, G. Degiacomi, A.L.d.J.L. Ribeiro, F. Zara, P. De Mori, B. Heym, M. Mirrione, R. Brerra, L. Pagani, L. Pucillo, P. Troupioti, V. Makarov, S.T. Cole, and G. Riccardi Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones Antimicrob. Agents Chemother. 54 2010 1616 1618
145. G. Manina, M. Bellinzoni, M.R. Pasca, J. Neres, A. Milano, A.L. De Jesus Lopes Ribeiro, S. Buroni, H. Škovierová, P. Dianiš ková, K. Mikušová, J. Marák, V. Makarov, D. Giganti, A. Haouz, A.P. Lucarelli, G. Degiacomi, A. Piazza, L.R. Chiarelli, E. De Rossi, E. Salina, S.T. Cole, P.M. Alzari, and G. Riccardi Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance Mol. Microbiol. 77 2010 1172 1185
146. T. Christophe, M. Jackson, H.K. Jeon, D. Fenistein, M. Contreras-Dominguez, J. Kim, A. Genovesio, J.-P. Carralot, F. Ewann, E.H. Kim, S.Y. Lee, S. Kang, M.J. Seo, E.J. Park, H. Škovierová, H. Pham, G. Riccardi, J.Y. Nam, L. Marsollier, M. Kempf, M.-L. Joly-Guillou, T. Oh, W.K. Shin, Z. No, U. Nehrbass, R. Brosch, S.T. Cole, and P. Brodin High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors PLoS Pathog. 5 2009 e1000645
147. P. Brodin, and T. Christophe High-content screening in infectious diseases Curr. Opin. Chem. Biol. 15 2011 534 539
148. J. Engohang-Ndong, D. Baillat, M. Aumercier, F. Bellefontaine, G.S. Besra, C. Locht, and A.R. Baulard EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator Mol. Microbiol. 51 2004 175 188 (Pubitemid 38031080)
149. N. Willand, B. Dirie, X. Carette, P. Bifani, A. Singhal, M. Desroses, F. Leroux, E. Willery, V. Mathys, R. Deprez-Poulain, G. Delcroix, F. Frenois, M. Aumercier, C. Locht, V. Villeret, B. Deprez, and A.R. Baulard Synthetic EthR inhibitors boost antituberculous activity of ethionamide Nat. Med. 15 2009 537 544
150. W. Weber, R. Schoenmakers, B. Keller, M. Gitzinger, T. Grau, M. Daoud-El Baba, P. Sander, and M. Fussenegger A synthetic mammalian gene circuit reveals antituberculosis compounds Proc. Natl. Acad. Sci. U S A 105 2008 9994 9998
151. D. Bonnel, R. Legouffe, N. Willand, A. Baulard, G. Hamm, B. Deprez, and J. Stauber MALDI imaging techniques dedicated to drug-distribution studies Bioanalysis 3 2011 1399 1406
152. M. Flipo, M. Desroses, N. Lecat-Guillet, B. Dirie, X. Carette, F. Leroux, C. Piveteau, F. Demirkaya, Z. Lens, P. Rucktooa, V. Villeret, T. Christophe, H.K. Jeon, C. Locht, P. Brodin, B. Deprez, A.R. Baulard, and N. Willand Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors J. Med. Chem. 54 2011 2994 3010
153. M. Flipo, M. Desroses, N. Lecat-Guillet, B. Villemagne, N. Blondiaux, F. Leroux, C. Piveteau, V. Mathys, M.-P. Flament, J. Siepmann, V. Villeret, A. Wohlkönig, R. Wintjens, S.H. Soror, T. Christophe, H.K. Jeon, C. Locht, P. Brodin, B. Deprez, A.R. Baulard, and N. Willand Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors J. Med. Chem. 55 2012 68 83